JPRN-UMIN000036038招募中未知
Efficacy of Ipragliflozin in type 1 diabetic patients - Efficacy of Ipragliflozin in type 1 diabetic patients
Ise Red Cross Hospital Department of Metabolic Diseases0 个研究点目标入组 50 人开始时间: 2019年3月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •Patients who had ketoacidosis or coma Malignancies or other diseases with poor prognosis eGFR<60mL/min/1.73m2
研究者
相似试验
已完成
不适用
Efficacy of ipragliflozin on diabetic nephropathy in patients with type 2 diabetesType 2 diabetes with/without diabetic nephropathyJPRN-UMIN000022615Ogawa Red Cross Hospital50
已完成
不适用
Effect of Ipragliflozin, a new oral hypoglycemic agent, on body composition in patients with diabetestype 2 diabetesJPRN-UMIN000014775Keio University School of Medicine, Internal Medicine30
进行中（未招募）
不适用
Treatment of type 1 diabetes with the drug liraglutide. The effects on blood sugar control, and metabolic hormones and function of the brain at low blood sugar levels.MedDRA version: 14.1Level: LLTClassification code 10045228Term: Type I diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersType 1 DiabetesEUCTR2012-002526-67-DKSten Madsbad
已完成
不适用
ong-term effects of ipragliflozin on diabetic nephropathy and blood pressure in patients with type 2 diabetesType 2 diabetes with diabetic nephropathyJPRN-UMIN000031157Ogawa Red Cross Hospital50
已完成
不适用
Efficacy of ipragliflozin on glucose metabolismtype 2 diabetes mellitusJPRN-UMIN000013921Shiraiwa Medical Clinic10